✦ LIBER ✦

Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis

✍ Scribed by Mr A. N. Kingsnorth; S. W. Galloway; L. J. Formela

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 763 KB
Volume: 82
Category: Article
ISSN: 0007-1323
DOI: 10.1002/bjs.1800821039

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multicenter, randomized, double-blind, a

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

✍ Vladimir Coric; Howard H. Feldman; Dan A. Oren; Anantha Shekhar; Joseph Pultz; R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

Rilonacept (Interleukin-1 Trap) in the p

Rilonacept (Interleukin-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial

✍ H. Ralph Schumacher Jr.; John S. Sundy; Robert Terkeltaub; Howard R. Knapp; Scot 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 3 views

Long-term safety and maintenance of clin

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

✍ George Nuki; Barry Bresnihan; Moraye B. Bear; Dorothy McCabe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 3 views

Golimumab, a new human anti–tumor necros

Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB 👁 1 views

Erratum: Golimumab, a new human anti–tum

Erratum: Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 1 views

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views